期刊论文Bispecific Antibody Toxicity复制

DOI:复制

文献链接: https://pubmed.ncbi.nlm.nih.gov/38753944复制

其他信息:

PMID: 38753944
作者: Suma Sri Chennapragada; Poornima Ramadas; Suma Sri Chennapragada; Suma Sri Chennapragada; Poornima Ramadas
摘要: Bispecific antibodies (bsAbs) have gained significant attention in recent years as a promising class of therapeutic agents designed to target multiple antigens simultaneously (see Image. Blinatumomab Mechanism of Action). These unique antibodies are engineered to recognize and bind to 2 distinct epitopes, allowing for a broader range of applications in treating various diseases, including cancer, autoimmune disorders, and infectious diseases. The FDA has already approved the following bsAbs for ...